Galantamine Alleviates Inflammation and Other Obesity-Associated Complications in High-Fat Diet-Fed Mice
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Obesity, a serious and growing health threat, is associated with low-grade inflammation that plays a role in mediating its adverse consequences. Previously, we have discovered a role for neural cholinergic signaling in controlling inflammation, and demonstrated that the cholinergic agent galantamine suppresses excessive proinflammatory cytokine release. The main objective of this study was to examine the efficacy of galantamine, a clinically-approved drug, in alleviating obesity-related inflammation and associated complications. After 8 wks on a high-fat diet, C57BL/6J mice were treated with either galantamine (4 mg/kg, intraperitoneally [i.p.]) or saline for 4 wks in parallel with mice on a low-fat diet and treated with saline. Galantamine treatment of obese mice significantly reduced body weight, food intake, abdominal adiposity, plasma cytokine and adipokine levels, and significantly improved blood glucose, insulin resistance and hepatic steatosis. In addition, galantamine alleviated impaired insulin sensitivity and glucose intolerance significantly. These results indicate a previously unrecognized potential of galantamine in alleviating obesity, inflammation and other obesity-related complications in mice. These findings are of interest for studying the efficacy of this clinically-approved drug in the context of human obesity and metabolic syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tracey, K. J. (2002) · Nature · doi:10.1038/nature01321 · Cited by 3,728
Self-citationMacrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
Kanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
Adipose tissue, adipokines, and inflammation
Fantuzzi, G. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.02.023 · Cited by 2,606 · cited 1×
“In contrast, decreased adiponectin levels in obese individuals inversely correlate with insulin resistance and hepatosteatosis (24,41).”
BackgroundCornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
Obesity, Inflammation, and Insulin Resistance
Shoelson, S. E., Herrero, L., & Naaz, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.059 · Cited by 1,806
Physiology and immunology of the cholinergic antiinflammatory pathway
Tracey, K. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30555 · Cited by 1,563
Self-citationOgden, C. L., Yanovski, S. Z., Carroll, M. D., & Flegal, K. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.052 · Cited by 1,561
Tracey, K. J. (2009) · Nature Reviews Immunology · doi:10.1038/nri2566 · Cited by 1,154
Self-citationSystemic inflammation and disease progression in Alzheimer disease
Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., & Perry, V. H. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b6bb95 · Cited by 1,139
Systemic infections and inflammation affect chronic neurodegeneration
Perry, V. H., Cunningham, C., & Holmes, C. (2007) · Nature Reviews Immunology · doi:10.1038/nri2015 · Cited by 1,027
The metabolic syndrome, inflammation, and risk of cognitive decline
Yaffe, K. (2004) · JAMA · doi:10.1001/jama.292.18.2237 · Cited by 1,025 · cited 1×
“Intriguingly, elevated serum markers of inflammation, including IL-6, in elderly people with the metabolic syndrome have been linked to significant cognitive impairment (58).”
BackgroundThe cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation
Pavlov, V. A., Wang, H., Czura, C. J., Friedman, S. G., & Tracey, K. J. (2003) · Molecular Medicine · doi:10.1007/bf03402177 · Cited by 772
Self-citationHypothalamic KATP channels control hepatic glucose production
Pocai, A., Lam, T. K. T., Gutierrez-Juarez, R., Obici, S., Schwartz, G. J., Bryan, J., Aguilar-Bryan, L., & Rossetti, L. (2005) · Nature · doi:10.1038/nature03439 · Cited by 645
The cholinergic anti-inflammatory pathway
Pavlov, V. A., & Tracey, K. J. (2005) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2005.03.015 · Cited by 622
Self-citationSurwit, R. S., Feinglos, M. N., Rodin, J., Sutherland, A., Petro, A. E., Opara, E. C., Kuhn, C. M., & Rebuffe-Scrive, M. (1995) · Metabolism · doi:10.1016/0026-0495(95)90123-x · Cited by 618
Pathology of nonalcoholic fatty liver disease
Brunt, E. M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.21 · Cited by 484
Heart rate variability in obesity and the effect of weight loss
Karason, K., Mølgaard, H., Wikstrand, J., & Sjöström, L. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00066-1 · Cited by 402 · cited 1×
“It is likely that these glucose homeostasis-controlling vagus nerve-mediated cholinergic mechanisms become suppressed or dysfunctional during obesity, as indicated by autonomic dysfunction and lower vagal tone in obese individuals (56,57).”
BackgroundA brain-liver circuit regulates glucose homeostasis
Pocai, A., Obici, S., Schwartz, G. J., & Rossetti, L. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2004.11.001 · Cited by 392
Central muscarinic cholinergic regulation of the systemic inflammatory response during endotoxemia
Pavlov, V. A., Ochani, M., Gallowitsch-Puerta, M., Ochani, K., Huston, J. M., Czura, C. J., Al-Abed, Y., & Tracey, K. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600506103 · Cited by 336
Self-citationNicotinic receptor‐mediated effects on appetite and food intake
Jo, Y., Talmage, D. A., & Role, L. W. (2002) · Journal of Neurobiology · doi:10.1002/neu.10147 · Cited by 323
The Metabolic Syndrome and Inflammation
Sutherland, J. P., McKinley, B., & Eckel, R. H. (2004) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2004.2.82 · Cited by 243
German, J., Kim, F., Schwartz, G. J., Havel, P. J., Rhodes, C. J., Schwartz, M. W., & Morton, G. J. (2009) · Endocrinology · doi:10.1210/en.2009-0445 · Cited by 164
Recent advances in nonalcholic fatty liver disease
Greenfield, V., Cheung, O., & Sanyal, A. J. (2008) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3282fbccf2 · Cited by 94
Visceral nerves: vagal and sympathetic innervation.
Teff, K. L. (2008) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607108321705 · Cited by 75
Cited by
The vagus nerve and the inflammatory reflex – linking immunity and metabolism
Pavlov, V. A., & Tracey, K. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.189 · Cited by 1,040
Self-citationSepsis: Current Dogma and New Perspectives
Deutschman, C. S., & Tracey, K. J. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.001 · Cited by 677
Self-citationMechanisms and Therapeutic Relevance of Neuro-immune Communication
Chavan, S. S., Pavlov, V. A., & Tracey, K. J. (2017) · Immunity · doi:10.1016/j.immuni.2017.06.008 · Cited by 663
Self-citationNeural regulation of immunity: molecular mechanisms and clinical translation
Pavlov, V. A., & Tracey, K. J. (2017) · Nature Neuroscience · doi:10.1038/nn.4477 · Cited by 532
Self-citationNicotinic acetylcholine receptors: From basic science to therapeutics
Hurst, R., Rollema, H., & Bertrand, D. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.08.012 · Cited by 522
Metadata
- Authors
- Satapathy, S. K., Ochani, M., Dancho, M., Hudson, L. K., Rosas-Ballina, M., Valdes-Ferrer, S. I., Olofsson, P. S., Harris, Y. T., Roth, J., Chavan, S., Tracey, K. J., & Pavlov, V. A.
- Venue
- Molecular Medicine
- Published
- 2011-07
- Volume
- 17
- Issue
- 7-8
- Pages
- 599-606
- ISSN
- 1076-1551 (ISSN-L)
- 1528-3658
- OpenAlex
- W145765351
- Cited by
- 119
- References
- 25
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.